Medical Affairs plays a critical role in life-cycle management. In this excerpt of "Defining the Course & Navigating the Finish Line," Dr. Crowley-Nowick discusses how to achieve better outcomes for patients using a synchronized approach, from development to commercialization. Medical Affairs in the Stern Steering also means adequately synchronizing the effort. The timing for strategy and execution of a Medical Affairs plan [...]
Our host Peg Crowley-Nowick and guest Christina Tankersley, PharmD, currently Sr. Director, Field Medical Team, Vaccines at Sanofi Pasteur discuss building, training, and maturing a diverse, multidisciplinary MSL team.
Are you challenged by siloed structures within your Medical Affairs organization? Our latest blog, by Julie Cahill, MD, V.P., Consulting and Medical Director Services, captures the essence and importance of cross-functional integration within Medical Affairs organizations.
Lumanity brings together a diverse collection of expert perspectives to uncover innovative yet pragmatic approaches to address the diverse and complex set of challenges associated with bringing medical advances to patients.
Our host Peg Crowley-Nowick and guest Tamas Suto, Head of Global MA Oncology at Merck KGaA, Darmstadt, Germany, discuss how leading Medical Affairs (MA) organizations have begun to strategically redefine their team’s requisite executional capabilities to enhance and tailor frontline engagement initiatives.
Partnering with an Alliance and aligning your medical strategy can be a daunting task. Zipher’s own Julie Cahill, MD outlines a unique approach for developing a concise medical strategy that drives impact and demonstrates value.
Arsenal Capital Partners, a private equity firm specializing in building healthcare businesses, today announced the acquisition of Zipher Medical Affairs, a leading provider of expert medical affairs strategic consulting services in the United States.
Insights provide the ability to gain a clear, deep, and sometimes unexpected understanding of a complicated problem or situation. In the pharmaceutical arena, insights are external trends that are actionable and have the potential to alter medical strategy
Host Peg Crowley-Nowick, PhD, MBA, Founder & President of Zipher Medical Affairs and Murial Siadak, PAC, spotlight the ever-increasing value and impact of insights on product strategy, positioning, and tactics.
Drs. Crowley-Nowick and Keir set the stage for a successful launch as they consider the key components of a MA Team and their contributions on the road to launch and beyond, from the formation and training of the Medical Science Liaison Team (MSLs) to the early inclusion of Medical Information, to developing best practices for Scientific Communications while also engaging with Patient Advocacy groups as part of the planning process.
Starting from the clinical trials and ending with meeting the regulatory demands across various countries, bringing a product to market successfully has become increasingly difficult. Therefore, it is critical that an overall launch strategy is established and executed.
Measuring the impact of the Medical Affairs (MA) organization is not as straightforward as it is for other functions (e.g., increase in revenue or market share for Commercial) and remains a challenge for most pharmaceutical companies today.
Zipher’s Medical Affairs unscripted features Dr. Zhen Su, an industry expert with over 20 years of experience and currently the Senior Vice President and Global Head of the Oncology Franchise for Merck, KGaA, Darmstadt, Germany to discuss how to develop the internal value of Medical Affairs as a strategic equal, improve cross-functional collaboration, and how to adapt to the virtual environment in this pandemic era and beyond.
Medical Affairs (MA) serves as a core scientific voice for the organization. With high competition and limited budget, it has grown increasingly more critical for Medical to meet their goals and key milestones at year-end.
Dr. Peg Crowley-Nowick, Founder & President of Zipher Medical Affairs is joined by Zipher’s own Julie Cahill, M.D., Vice President of Consulting and Medical Director Services to continue the conversation from the episode "Data Generation | The Intersection Between Medical Affairs and Clinical Development" by expanding further on the need to identify data gaps and how organizations can work together to consider the full scope of research that can be used to fill those gaps.
As the Zipher Medical Affairs unscripted podcast series continues to distinguish Medical Affairs as one of the major pillars of biopharmaceutical organizations, Dr. Peg Crowley-Nowick, Founder & President of Zipher Medical Affairs hosts Dr. Adam Schayowitz, an industry veteran and current Vice President and Medicine Team Lead at Pfizer, to discuss the intersection between Medical Affairs (medical) and Clinical Development (development) with regards to data generation as medical continues its evolution as the third pillar in industry.
This episode of Zipher’s Medical Affairs unscripted features Randi Goeckeler, an industry expert with over 25 years of experience and most recently the Executive Director of Global Stakeholder Relations at Allergan, who discusses how to build an integrated, strategic stakeholder relations program to accelerate availability of treatments for patients and ultimately help them have better outcomes.
During this episode of Medical Affairs unscripted, Dr. Crowley-Nowick has a conversation with Holly Schachner, MD, former CMO of Specialty Medicine at Allergan to examine the business objective of Medical Affairs (MA) organizations and how MA can move closer to being identified as a strategic pillar within the life sciences industry alongside the Research & Development and Commercial organizations.
During this webcast, you will learn from industry experts Peg Crowley-Nowick, PhD, MBA President of Zipher Medical Affairs Co., LLC. and Christopher Keir, MD, MS as they share key strategies for an effective and efficient approach to success in launch preparation.
In this episode of Medical Affairs unscripted, President and Founder Peg Crowley-Nowick has a conversation with Dan Hennessy. They discuss reaching the right stakeholders, who they are, how important it is to engage and have scientific exchange, and what the risks are for not doing this well.